|
|
Article: New PSA test that may help differentiate between prostate cancer and BPH to be announced at annual meeting of the American Urological Association (AUA); DIANON Systems and University of Washington collaborate on a new development in the detection of Prostate Specific Antigen (PSA); Improved diagnostic performance of new PSA test in "diagnostic grey zone" of PSA values between 4.0 - 10.0 ng/ml may help eliminate numerous, unnecessary,.(umerous, unnecessary,.)
- Article from:
- Business Wire
- Article date:
- April 20, 1995
CopyrightCOPYRIGHT 1995 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
STRATFORD, Conn.--(BUSINESS WIRE)--April 20, 1995--Researchers at the University of Washington Medical Center and scientists at DIANON Systems Inc. (NASDAQ: DIAN) have developed a second-generation prostate cancer test, PSA II, that may be able to better discriminate between prostate cancer and BPH, or benign prostatic hyperplasia.
A study describing this potential breakthrough development has been accepted for publication in Urology and will be presented at next week's 1995 Annual Meeting of the American Urological Association (AUA) in Las Vegas.
Prostate specific antigen (PSA) is widely used as a clinical marker of prostate cancer. The PSA test measures ...